Latest Derivatives News

Page 41 of 41
Global Masters Fund Limited's latest quarterly report confirms compliance with all financial obligations and highlights a recent interest rate increase on its convertible notes, supported by a robust loan-to-value ratio.
Claire Turing
Claire Turing
24 Jan 2025
Altech Batteries’ CERENERGY® sodium chloride battery project has secured the highest environmental rating, ‘Dark Green,’ from S&P Global Ratings, highlighting its low emissions and sustainable production. This accreditation opens access to the growing Green Bond market, positioning Altech as a leader in eco-friendly battery technology.
Maxwell Dee
Maxwell Dee
24 Jan 2025
Surefire Resources NL's maiden drilling at Copper Hill reveals increasing copper and sulfur levels, signaling promising mineralization beneath surface anomalies. A geophysical survey is set to refine target zones for follow-up exploration.
Maxwell Dee
Maxwell Dee
23 Jan 2025
Battery Age Minerals has verified the presence of Germanium-76 in concentrate from Austria’s historic Bleiberg mine, positioning the project as a strategic supplier for semiconductor materials amid tightening global supply.
Maxwell Dee
Maxwell Dee
22 Jan 2025
Core Energy Minerals has entered staged option agreements to acquire up to 100% interests in the Cummins and Harris Greenstone uranium projects, expanding its footprint in South Australia's premier uranium mining jurisdiction.
Maxwell Dee
Maxwell Dee
21 Jan 2025
Arrow Minerals reports exceptional metallurgical testwork results from its Simandou North Iron Project, revealing a high-grade, low-alumina hematite fines product with strong potential for premium pricing. This milestone follows a strategic MoU with Baosteel, positioning Arrow for accelerated project development.
Maxwell Dee
Maxwell Dee
15 Jan 2025
PWR Holdings' North American arm, C&R Racing Inc., has landed a $8.9 million AUD order to supply advanced cooling systems for a US government aerospace project, marking a pivotal milestone in its defence sector expansion.
Victor Sage
Victor Sage
14 Jan 2025
Immuron has submitted its Phase 2 clinical study report for Travelan® to the FDA, revealing statistically significant immunological and microbiome benefits. The company is preparing to engage the FDA for Phase 3 trial discussions while progressing a large field study with military personnel.
Ada Torres
Ada Torres
14 Jan 2025